HuGE Literature Finder
Records
1
-
10
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer. NPJ breast cancer 2022 Feb 8 (1): 24. Migliaccio Ilenia, Paoli Marta, Risi Emanuela, Biagioni Chiara, Biganzoli Laura, Benelli Matteo, Malorni Lu |
Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Jun . Sun Xiangjie, Zuo Ke, Yao Qianlan, Zhou Shuling, Shui Ruohong, Xu Xiaoli, Bi Rui, Yu Baohua, Cheng Yufan, Tu Xiaoyu, Lu Hongfen, Yang Went |
Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast cancer research : BCR 2020 May 22 (1): 45. Martínez-Sáez Olga, Chic Nuria, Pascual Tomás, Adamo Barbara, Vidal Maria, González-Farré Blanca, Sanfeliu Esther, Schettini Francesco, Conte Benedetta, Brasó-Maristany Fara, Rodríguez Adela, Martínez Débora, Galván Patricia, Rodríguez Ana Belén, Martinez Antonio, Muñoz Montserrat, Prat Ale |
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Annals of oncology : official journal of the European Society for Medical Oncology 2020 May . Karn T, Denkert C, Weber K E, Holtrich U, Hanusch C, Sinn B V, Higgs B W, Jank P, Sinn H P, Huober J, Becker C, Blohmer J-U, Marmé F, Schmitt W D, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P A, Jackisch C, Untch M, Schneeweiss A, Loibl |
Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2020 Mar 31 (3): 387-394. Barroso-Sousa R, Jain E, Cohen O, Kim D, Buendia-Buendia J, Winer E, Lin N, Tolaney S M, Wagle |
Protein interaction disruption in cancer. BMC cancer 2019 Apr 19 (1): 370. Ruffalo Matthew, Bar-Joseph Z |
Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Bone marrow transplantation 2016 Apr . Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra J-M, Tarpin C, Houvenaegel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher J-M, Viens P, Eisinger F, Chabannon |
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 May 26 (5): 914-20. Monk B J, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita A S, Nieto A, Park Y C, Cheng P S, Li W, Favis R, Ricci D, Poveda |
Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of articledeveloping erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. BMC cancer 2011 11 (1): 291. Falvo Elisabetta, Strigari Lidia, Citro Gennaro, Giordano Carolina, Arcangeli Stefano, Soriani Antonella, D'Alessio Daniela, Muti Paola, Blandino Giovanni, Sperduti Isabella, Pinnarò Pao |
Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. International journal of cancer. Journal international du cancer 2003 Sep 106 (4): 588-93. de Sanjosé Silvia, Léoné Mélanie, Bérez Victoria, Izquierdo Angel, Font Rebeca, Brunet Joan M, Louat Thierry, Vilardell Loreto, Borras Joan, Viladiu Pau, Bosch F Xavier, Lenoir Gilbert M, Sinilnikova Olga |
- Page last reviewed:Oct 1, 2021
- Page last updated:May 20, 2022
- Content source: